NewTimeSpace News:As of 13:18 on February 5, 2026, the CSI All-Cap Medical & Health Index (000991) rose 0.09%. Among its constituent stocks, Aesthetic Medical International Holdings Group Co., Ltd. rose 4.77%, Darentang Pharmaceutical Co., Ltd. climbed 4.26%, Jinbo Biotechnology Co., Ltd. advanced 3.66%, Pien Tze Huang Pharmaceutical Co., Ltd. increased by 3.63%, and Tongce Medical Investment Group Co., Ltd. gained 3.58%. TheGF CSI All Share Health Care Index ETF (159938) rose 0.30%, approaching a three-day winning streak, with the latest price at RMB 0.66. Over a longer time frame, as of February 4, 2026, the ETF had achieved a cumulative increase of 1.39% in the past month. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

In terms of liquidity, theGF CSI All Share Health Care Index ETF recorded an intraday turnover rate of 0.38% and a trading volume of RMB 20.3047 million. Looking back, as of February 4, the ETF's average daily trading volume in the past month reached RMB 90.9193 million.

Regarding scale, the latest size of theGF CSI All Share Health Care Index ETF stood at RMB 5.282 billion. (Data source: Wind)

Data shows that leveraged capital has been continuously deploying in the ETF. The latest margin purchase amount of theGF CSI All Share Health Care Index ETF reached RMB 2.1648 million, and the latest margin trading balance stood at RMB 30.1120 million. (Data source: Wind)

As of February 4, theGF CSI All Share Health Care Index ETF had a NAV increase of 16.77% in the past two years. In terms of profitability, as of February 4, 2026, since its establishment, the ETF has achieved a maximum monthly return of 22.34%, the longest consecutive monthly growth period of 8 months with a cumulative increase of 67.34%, a ratio of rising to falling months of 72:62, and an average monthly return of 5.58% in upward months. As of February 4, 2026, the ETF's annualized excess return over the benchmark since its establishment was 1.31%.

Regarding drawdown, as of February 4, 2026, the ETF's maximum drawdown since the beginning of the year was 8.76%, with a relative benchmark drawdown of 0.03%.

In terms of fees, theGF CSI All Share Health Care Index ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

For tracking accuracy, as of February 4, 2026, the ETF's tracking error in the past two months was 0.009%.

Notably, the valuation of the CSI All-Cap Medical & Health Index tracked by the fund is at a historical low. The latest price-to-book ratio (PB) is 3.21 times, lower than 83.86% of the time since the index was established, highlighting prominent valuation cost-effectiveness.

TheGF CSI All Share Health Care Index ETF closely tracks the CSI All-Cap Medical & Health Index. The CSI All-Cap Industry Preferred Index Series selects listed companies that meet certain liquidity and market capitalization screening criteria from CSI All-Cap Industries as index samples to reflect the overall performance of representative and investable listed company securities in various industries.

Data shows that as of January 30, 2026, the top 10 weight stocks of the CSI All-Cap Medical & Health Index (000991) were Hengrui Medicine Co., Ltd., WuXi AppTec Co., Ltd., Mindray Medical International Limited, United Imaging Healthcare Co., Ltd., Aier Eye Hospital Group Co., Ltd., Yunnan Baiyao Group Co., Ltd., Pien Tze Huang Pharmaceutical Co., Ltd., NHU Co., Ltd., Kelun Pharmaceutical Co., Ltd., and Fosun Pharmaceutical (Group) Co., Ltd., with a combined weight of 38.7%. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

CHANGJIANG SECURITIES stated that since 2025, Chinese innovative drug companies have seen an increase in capital availability and a stronger willingness to invest in R&D. The prosperity of R&D investment in Chinese innovative drugs may gradually improve, leading the innovative drug industry chain to enter a new round of prosperity cycle. Under the trend of external BD (Business Development), the domestic demand early R&D industry chain is expected to benefit significantly.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.